A randomized controlled trial demonstrates that low-frequency rTMS targeting the orbitofrontal cortex improves positive symptoms and attentional alertness in schizophrenia, mediated by dynamic modularity between the OFC and default mode network.
This theoretical paper proposes a mechanistic model for psilocybin-induced neuroplasticity, addressing the paradox between 5-HT2A receptor activation and TrkB signaling, which informs the biological basis of psychedelic-assisted therapy.
A new analysis of BXCL501 demonstrates its efficacy in reducing agitation in patients with bipolar disorder and schizophrenia when administered at home, supporting its clinical utility for acute management.
The VA has launched a new clinical trial for MDMA, and recent data indicates psilocybin's antidepressant effects are both rapid and long-lasting, highlighting ongoing research into novel psychedelic treatments for psychiatric conditions.
This article examines antipsychotic prescribing patterns in Ugandan pediatric epilepsy patients, representing a prescribing-pattern study relevant to psychopharmacology practice.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 29 – May 30)
- Monitor patients closely for hypomania or mania when considering psychedelic-assisted therapies, as systematic reviews highlight this as a significant safety risk.
- Consider low-frequency rTMS targeting the orbitofrontal cortex as an adjunctive option for schizophrenia patients with prominent positive symptoms and attentional deficits.
- Utilize BXCL501 for the acute management of agitation in bipolar disorder and schizophrenia, noting its demonstrated efficacy in home-based settings.
- Prioritize NMDA antagonists with intermediate ion-trapping properties, such as ketamine, for treating major depressive disorder, as sustained modulation of negative affective biases predicts clinical efficacy.
- Recognize that psilocybin's antidepressant effects are characterized by both rapid onset and long-lasting duration, informing treatment planning for novel psychedelic interventions.
- Review antipsychotic prescribing patterns in pediatric epilepsy patients to ensure appropriate pharmacological management of comorbid psychiatric symptoms.
- Understand that psilocybin-induced neuroplasticity involves a complex interplay between 5-HT2A receptor activation and TrkB signaling, which underpins its therapeutic mechanism.
- Be aware that the VA has launched new clinical trials for MDMA, reflecting the expanding landscape of psychedelic research in psychiatric care.
Diagnosis & Treatment 1
This systematic review and meta-analysis evaluates the incidence and risk factors of psychedelic-induced hypomania and mania, providing critical safety data for clinicians considering psychedelic-assisted therapies.
Mechanism of Action 1
Preclinical research suggests that sustained modulation of negative affective biases by NMDA antagonists, particularly those with intermediate ion-trapping properties like ketamine, may predict clinical efficacy in major depressive disorder.